Literature DB >> 11022874

Homocysteine elevation in sickle cell disease.

E A Lowenthal1, M S Mayo, P E Cornwell, D Thornley-Brown.   

Abstract

OBJECTIVE: Ischemic complications are common in patients with sickle cell disease. Hyperhomocysteinemia is a risk factor for arteriosclerosis and venous thrombosis, and given the propensity of patients with sickle cell disease to develop ischemic complications, we hypothesized that they might have elevated plasma homocysteine concentrations.
METHODS: Plasma concentrations of homocysteine, vitamin B12 and folate were measured in 49 adults with sickle cell disease and 16 normotensive Black controls. All subjects with sickle cell disease had been prescribed folic acid 1 mg by mouth daily.
RESULTS: The median plasma concentration of homocysteine of subjects with sickle cell disease was approximately 1.5-fold higher than that of controls (p=0.0008). This difference persisted, even when subjects with renal insufficiency were excluded. Plasma folate levels were 1.5-fold higher in subjects with sickle cell disease than in controls (p=0.0498). There was no significant difference in plasma vitamin B12 concentrations between the two groups. There was no difference in plasma homocysteine concentrations between transfused and non-transfused sickle cell subjects.
CONCLUSIONS: Patients with sickle cell disease have elevated plasma concentrations of homocysteine in spite of elevated plasma folate levels and vitamin B12 concentrations similar to those observed in controls. Based on these data, we hypothesize that the concentration of folate required to normalize plasma homocysteine levels in patients with sickle cell disease may be higher than that of normal controls and that patients with sickle cell disease have a higher nutritional requirement for folic acid than the general population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022874     DOI: 10.1080/07315724.2000.10718958

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  6 in total

1.  Atherosclerosis in sickle cell disease - a review.

Authors:  Mohamed A Elsharawy; Khaled M Moghazy; Mohamed A Shawarby
Journal:  Int J Angiol       Date:  2009

2.  Homocysteine is associated with severity of microvasculopathy in sickle cell disease patients.

Authors:  Sandra L Samarron; Joshua W Miller; Anthony T Cheung; Peter C Chen; Xin Lin; Theodore Zwerdling; Ted Wun; Ralph Green
Journal:  Br J Haematol       Date:  2020-04-19       Impact factor: 6.998

3.  Stroke in Children with Sickle Cell Disease.

Authors:  Fenella J. Kirkham; Michael R. DeBaun
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

4.  Cobalamin status in sickle cell disease.

Authors:  O I Ajayi; S Bwayo-Weaver; S Chirla; M Serlemitsos-Day; M Daniel; M Nouraie; K Edwards; O Castro; F Lombardo; V R Gordeuk
Journal:  Int J Lab Hematol       Date:  2012-07-26       Impact factor: 2.877

5.  Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage.

Authors:  Vasundhara Kain; Sandeep Kumar; Amrutesh S Puranik; Sandhya L Sitasawad
Journal:  Cardiovasc Diabetol       Date:  2010-12-01       Impact factor: 9.951

6.  Concurrent Bilateral Central Retinal Artery Occlusion Secondary to Sickle Cell Crisis.

Authors:  Gowri Renganathan; Piruthiviraj Natarajan; Lela Ruck; Roberto Prieto; Bharat Ved Prakash; Sudhagar Thangarasu
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.